Football’s hidden brain disease can be confirmed only after death. A blood test just flagged its worst cases while patients were alive
The test measures a piece of the brain protein tau. It missed early CTE and can’t tell CTE from Alzheimer’s on its own, so it isn’t ready for patients.
A blood test for a piece of tau, a brain protein, came back higher in people later found to have chronic traumatic encephalopathy, or CTE, than in healthy people, according to a study published Nov. 13 in JAMA. CTE is brain damage linked to repeated blows to the head, and it can be diagnosed only by examining the brain after death, the Defense Department’s brain injury center says.
The blood was drawn from patients while they were alive at UCSF’s Memory and Aging Center, and UCSF’s brain bank later confirmed CTE at autopsy. Washington University in St. Louis led the study; several UCSF researchers are co-authors.
What it means
For former football players, boxers, veterans and their families, there is still no test for CTE in living people. This is an early research step, not a test anyone can order. The same tau piece rises even higher in Alzheimer’s disease, so by itself it can’t tell the two apart, and it did not reliably detect early CTE. The authors say it would have to be combined with a person’s history of head hits and Alzheimer’s tests, then checked in much larger groups.
What the study found
Tau normally helps hold the inside of nerve cells together, but in some diseases it clumps into tangles. It comes in two main forms. The fragment, called eMTBR-tau243, rose in diseases where both forms clump together, such as Alzheimer’s and CTE, but not in diseases involving only one form.
In blood from 11 people with CTE, the typical level was about 6.6 times that of 20 healthy people with no head trauma. Levels climbed with the disease’s stage. On a standard accuracy scale where 1 is perfect and 0.5 is a coin flip, the test scored 0.97 at separating the six people with stage III or IV CTE, the most advanced stages, from healthy people. For the five with stage I, it scored 0.64, a result the authors say was not reliable. Fourteen people with Alzheimer’s had levels about six times higher than the CTE group.
The numbers are small, and nine of the 11 CTE patients were men; the authors note that most brain donors with CTE are men who played contact sports. The study did not account systematically for how long before death the blood was drawn. In all, it tested blood or spinal fluid from 229 people from four U.S. sample banks, using mass spectrometry, a lab method that identifies molecules by weight.
Lead author Kanta Horie is paid by drugmaker Eisai and holds tau-test patents licensed to C2N Diagnostics, a St. Louis company that sells Alzheimer’s blood tests, which the journal lists as outside this work. The National Institutes of Health funded the study, which was presented Saturday at a dementia research meeting in Tsukuba, Japan.
Source: Horie et al., “Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology,” JAMA, Nov. 13, 2026; Defense Health Agency, Traumatic Brain Injury Center of Excellence, CTE frequently asked questions.
- JAMA: Horie et al., Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology (published online Nov. 13, 2026; doi:10.1001/jama.2026.24689)
- Defense Health Agency, Traumatic Brain Injury Center of Excellence: Chronic Traumatic Encephalopathy (CTE) Frequently Asked Questions (revised March 2023)
- C2N Diagnostics company website (St. Louis; Precivity Alzheimer’s blood tests)